Development of a novel centrosome-related risk signature to predict prognosis and treatment response in lung adenocarcinoma
Abstract Background Abnormalities of centrosomes, the major microtubular organizing centers of animal cells and regulators of cell cycle progression, usually accelerate tumor progression, but their prognostic value in lung adenocarcinoma (LUAD) remains insufficiently explored. Methods We collected c...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2024-11-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-024-01615-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846147669134671872 |
|---|---|
| author | Ziqiang Wang Chao Zuo Jiaojiao Fei Huili Chen Luyao Wang Yiluo Xie Jing Zhang Shengping Min Xiaojing Wang Chaoqun Lian |
| author_facet | Ziqiang Wang Chao Zuo Jiaojiao Fei Huili Chen Luyao Wang Yiluo Xie Jing Zhang Shengping Min Xiaojing Wang Chaoqun Lian |
| author_sort | Ziqiang Wang |
| collection | DOAJ |
| description | Abstract Background Abnormalities of centrosomes, the major microtubular organizing centers of animal cells and regulators of cell cycle progression, usually accelerate tumor progression, but their prognostic value in lung adenocarcinoma (LUAD) remains insufficiently explored. Methods We collected centrosome genes from the literature and identified LUAD-specific centrosome-related genes (CRGs) using the single-sample gene set enrichment analysis (ssGSEA) algorithm and weighted gene co-expression network analysis (WGCNA). Univariate Cox was performed to screen prognostic CRGs. Consistent clustering was performed to classify LUAD patients into two subgroups, and centrosome-related risk score signatures were constructed by Lasso and multivariate Cox regression to predict overall survival (OS). We further explored the correlation between CRS and patient prognosis, clinical manifestations, mutation status, tumor microenvironment, and response to different treatments. Results We constructed centrosome-associated prognostic features and verified that CRS could effectively predict 1-, 3-, and 5-year survival in LUAD patients. In addition, patients in the high-risk group exhibited elevated tumor mutational loads and reduced levels of immune infiltration, particularly of T and B cells. Patients in the high-risk group were resistant to immunotherapy and sensitive to 5-fluoropyrimidine and gefitinib. The key gene spermine synthase (SRM) is highly expressed at the mRNA and protein levels in LUAD. Discussion Our work develops a novel centrosome-related prognostic signature that accurately predicts OS in LUAD and can assist in clinical diagnosis and treatment. |
| format | Article |
| id | doaj-art-5a07296748b643158f6a9ea6af06b1db |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-5a07296748b643158f6a9ea6af06b1db2024-12-01T12:32:34ZengSpringerDiscover Oncology2730-60112024-11-0115112310.1007/s12672-024-01615-8Development of a novel centrosome-related risk signature to predict prognosis and treatment response in lung adenocarcinomaZiqiang Wang0Chao Zuo1Jiaojiao Fei2Huili Chen3Luyao Wang4Yiluo Xie5Jing Zhang6Shengping Min7Xiaojing Wang8Chaoqun Lian9Anhui Province Key Laboratory of Respiratory Tumor and Infectious Disease, Department of Pulmonary and Critical Care Medicine, Molecular Diagnosis Center, First Affiliated Hospital of Bengbu Medical UniversityDepartment of Clinical Laboratory, Affiliated Hospital of Guilin Medical UniversityAnhui Province Key Laboratory of Respiratory Tumor and Infectious Disease, Department of Pulmonary and Critical Care Medicine, Molecular Diagnosis Center, First Affiliated Hospital of Bengbu Medical UniversityResearch Center of Clinical Laboratory Science, Bengbu Medical UniversityDepartment of Genetics, School of Life Sciences, Bengbu Medical UniversityDepartment of Clinical Medicine, Bengbu Medical UniversityDepartment of Genetics, School of Life Sciences, Bengbu Medical UniversityAnhui Province Key Laboratory of Respiratory Tumor and Infectious Disease, Department of Pulmonary and Critical Care Medicine, Molecular Diagnosis Center, First Affiliated Hospital of Bengbu Medical UniversityAnhui Province Key Laboratory of Respiratory Tumor and Infectious Disease, Department of Pulmonary and Critical Care Medicine, Molecular Diagnosis Center, First Affiliated Hospital of Bengbu Medical UniversityResearch Center of Clinical Laboratory Science, Bengbu Medical UniversityAbstract Background Abnormalities of centrosomes, the major microtubular organizing centers of animal cells and regulators of cell cycle progression, usually accelerate tumor progression, but their prognostic value in lung adenocarcinoma (LUAD) remains insufficiently explored. Methods We collected centrosome genes from the literature and identified LUAD-specific centrosome-related genes (CRGs) using the single-sample gene set enrichment analysis (ssGSEA) algorithm and weighted gene co-expression network analysis (WGCNA). Univariate Cox was performed to screen prognostic CRGs. Consistent clustering was performed to classify LUAD patients into two subgroups, and centrosome-related risk score signatures were constructed by Lasso and multivariate Cox regression to predict overall survival (OS). We further explored the correlation between CRS and patient prognosis, clinical manifestations, mutation status, tumor microenvironment, and response to different treatments. Results We constructed centrosome-associated prognostic features and verified that CRS could effectively predict 1-, 3-, and 5-year survival in LUAD patients. In addition, patients in the high-risk group exhibited elevated tumor mutational loads and reduced levels of immune infiltration, particularly of T and B cells. Patients in the high-risk group were resistant to immunotherapy and sensitive to 5-fluoropyrimidine and gefitinib. The key gene spermine synthase (SRM) is highly expressed at the mRNA and protein levels in LUAD. Discussion Our work develops a novel centrosome-related prognostic signature that accurately predicts OS in LUAD and can assist in clinical diagnosis and treatment.https://doi.org/10.1007/s12672-024-01615-8Lung adenocarcinomaCentrosomeCRSPrognostic modelTumor microenvironment |
| spellingShingle | Ziqiang Wang Chao Zuo Jiaojiao Fei Huili Chen Luyao Wang Yiluo Xie Jing Zhang Shengping Min Xiaojing Wang Chaoqun Lian Development of a novel centrosome-related risk signature to predict prognosis and treatment response in lung adenocarcinoma Discover Oncology Lung adenocarcinoma Centrosome CRS Prognostic model Tumor microenvironment |
| title | Development of a novel centrosome-related risk signature to predict prognosis and treatment response in lung adenocarcinoma |
| title_full | Development of a novel centrosome-related risk signature to predict prognosis and treatment response in lung adenocarcinoma |
| title_fullStr | Development of a novel centrosome-related risk signature to predict prognosis and treatment response in lung adenocarcinoma |
| title_full_unstemmed | Development of a novel centrosome-related risk signature to predict prognosis and treatment response in lung adenocarcinoma |
| title_short | Development of a novel centrosome-related risk signature to predict prognosis and treatment response in lung adenocarcinoma |
| title_sort | development of a novel centrosome related risk signature to predict prognosis and treatment response in lung adenocarcinoma |
| topic | Lung adenocarcinoma Centrosome CRS Prognostic model Tumor microenvironment |
| url | https://doi.org/10.1007/s12672-024-01615-8 |
| work_keys_str_mv | AT ziqiangwang developmentofanovelcentrosomerelatedrisksignaturetopredictprognosisandtreatmentresponseinlungadenocarcinoma AT chaozuo developmentofanovelcentrosomerelatedrisksignaturetopredictprognosisandtreatmentresponseinlungadenocarcinoma AT jiaojiaofei developmentofanovelcentrosomerelatedrisksignaturetopredictprognosisandtreatmentresponseinlungadenocarcinoma AT huilichen developmentofanovelcentrosomerelatedrisksignaturetopredictprognosisandtreatmentresponseinlungadenocarcinoma AT luyaowang developmentofanovelcentrosomerelatedrisksignaturetopredictprognosisandtreatmentresponseinlungadenocarcinoma AT yiluoxie developmentofanovelcentrosomerelatedrisksignaturetopredictprognosisandtreatmentresponseinlungadenocarcinoma AT jingzhang developmentofanovelcentrosomerelatedrisksignaturetopredictprognosisandtreatmentresponseinlungadenocarcinoma AT shengpingmin developmentofanovelcentrosomerelatedrisksignaturetopredictprognosisandtreatmentresponseinlungadenocarcinoma AT xiaojingwang developmentofanovelcentrosomerelatedrisksignaturetopredictprognosisandtreatmentresponseinlungadenocarcinoma AT chaoqunlian developmentofanovelcentrosomerelatedrisksignaturetopredictprognosisandtreatmentresponseinlungadenocarcinoma |